| PRME Etf | | | USD 3.45 0.16 4.86% |
Andrew MD is Portfolio Manager at Prime Medicine, Common
| Age | 37 |
| Address | 21 Erie Street, Cambridge, MA, United States, 02139 |
| Phone | 617 564 0013 |
| Web | https://primemedicine.com |
Prime Medicine, Management Efficiency
The company has return on total asset
(ROA) of
(0.4651) % which means that it has lost $0.4651 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(1.1435) %, meaning that it created substantial loss on money invested by shareholders. Prime Medicine,'s management efficiency ratios could be used to measure how well Prime Medicine, manages its routine affairs as well as how well it operates its assets and liabilities.
Prime Medicine, Common currently holds 13.63
M in liabilities with Debt to Equity
(D/E) ratio of 0.18, which may suggest the company is not taking enough advantage from borrowing. Prime Medicine, Common has a current ratio of 6.57, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Debt can assist Prime Medicine, until it has trouble settling it off, either with new capital or with free cash flow. So, Prime Medicine,'s shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Prime Medicine, Common sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Prime to invest in growth at high rates of return. When we think about Prime Medicine,'s use of debt, we should always consider it together with cash and equity.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. Prime Medicine is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange. Prime Medicine, Common [PRME] is traded in USA and was established 2015-11-11. Prime Medicine, is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Prime Medicine, Common Money Managers
| David Liu, CoFounder Board | |
| Meredith Goldwasser, Senior Operations | |
| Andrew MD, CoFounder Platform | |
| Richard Brudnick, Chief Officer | |
| Keith MD, CEO and President | |
| Ann Lee, Chief Officer | |
| Karen JD, Senior Affairs | |
| Allan MD, Chief Officer | |
| Niamh Alix, Chief Officer | |
| Keith Gottesdiener, CEO and Presidentident | |
Prime Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is Prime Medicine, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Other Information on Investing in Prime Etf
Prime Medicine, financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine, security.